In a multicenter randomized prospective trial that investigated moderate to severe Crohn’s disease, a significantly greater proportion of patients treated with a first-line anti-TNF-α therapy achieved clinical and endoscopic remission (20). The gene discussed is TNF; the disease is Crohn disease.